Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: ATTR Amyloidosis With Cardiomyopathy Clear all

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions: Eplontersen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 46
States / cities: Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 35 more

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions: Eplontersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 51
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 39 more

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions: Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: Placebo, Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more

Conditions: Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions: ALXN2220; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 35
States / cities: Irvine, California • La Jolla, California • Palo Alto, California + 29 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Stanford, California + 5 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001, Placebo (NNC6019-0001); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Beverly Hills, California • Stanford, California + 5 more

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
Interventions: acoramidis, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more

Conditions: Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
Interventions: AG10, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 13
States / cities: Beverly Hills, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Interventions: Scintigraphy; Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 22
States / cities: Fairhope, Alabama • Huntsville, Alabama • Miami, Florida + 11 more

Conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions: Not listed
Lead sponsor: eMyosound SAS; Industry
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Amyloidosis
Interventions: Inotersen; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: Tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 41
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related
Interventions: Acoramidis (AG10); Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 26
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more

Conditions: Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
Interventions: tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Study of AG10 in Amyloid Cardiomyopathy

Global Prevalence of ATTR-CM in Participants With HFpEF

US Benchmarking Clinical Study

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis